Peer health/ philippines - cycle 2
PEER Health closed the call for concept notes Cycle 2 on March 14, 2014.
Research Focus: TB in Children
Located in Southeast Asia, the Philippines is an archipelago of 7,100 islands with an estimated total population of 93 million in 2010, of which 19 million are below 10 years old and 11 million are below 5 years old. According to the Global Health Report, the Philippines ranks ninth out of 22 countries with high TB burden. In 2012, the TB mortality registered 29 deaths per 100,000 population (target: less than 44/100,000 in 2016), while the prevalence rate at 484/100,000 (target: less than 400/100,000 in 2016).
Through the National Tuberculosis Control Program (NTP) of the Department of Health (DOH), the country was able to achieve an 82% case detection rate of all forms of TB and a treatment success rate of 90% in 2012. In 2009, the NTP developed the 2010-2016 Philippine Plan of Action to Control TB (PhilPACT), which is currently being enhanced for 2014-2016. The PhilPACT includes strategies for the management of TB among the vulnerable populations such as children.
Of the estimated 730,000 children with TB, only 87,936 children (12%) were provided with treatment or preventive therapy. The proportion of TB in children (<14 years old) notified to NTP was 1% and although there was an increase over time, its proportion relative to other TB cases did not exceed 2% from 2003 to 2011. The diagnosis and treatment of childhood tuberculosis remains challenging. Reducing the burden of TB in children will require changing and improving many existing practices, such as the utilization of innovative rapid diagnostic tools, like GeneXpert, and effective treatment regimens that have a high adherence rate. To advance the development objectives of NTP and USAID/Philippines, PEER Health/Philippines will support country-specific research needed for evidence-based programming of TB control and prevention. Anchored on the directions of the NTP, the research focus of solicitation is TB in children.
Download the Philippines Request for Application as PDF.
Applicants who have questions
after reviewing the materials on
this Web site are encouraged to
contact PEER Health staff by e-mail
In alignment with research priorities on TB and children, the United States National Cancer Institute (NCI) is interested in supporting studies through this solicitation that would assess family-oriented tobacco control interventions within the TB treatment setting. There is a substantial body of evidence linking tobacco use and TB outcomes, including susceptibility to infection, progression to active disease, relapse, and treatment failure. Passive smoke exposure may also increase the risk for spread of TB in households. Almost half (48%) of Filipino adult men smoke cigarettes and many children are exposed to secondhand smoke at home. WHO guidelines recommend support for smoking cessation within TB treatment programs. However, limited data exists to evaluate the efficacy or cost-effectiveness of such programs in practice.
For more information on the following programs see the links below:
This PEER Health/ Philippines solicitation is focused on TB in children. Applicants are encouraged to address their research studies on critical questions in this area. Priority research topics may also include the topics listed below:
- Sensitivity and specificity of GeneXpert in diagnosing new smear negative cases, including children
- Analysis of the barriers to the implementation of isoniazid prevention therapy for children
- Development/introduction of innovative diagnostic/treatment products in the management of TB in children.
- Assessment of family-oriented tobacco control within TB treatment setting:
- Developing and evaluating cessation interventions for controlling the spread of TB within households and limiting the impact on the health of children.
- Determining the outcome of TB treatment among children exposed to second hand smoke at home.
Projects with a research focus on the development and/or implementation of mobile technology or other electronic tools with regard to TB prevention and control in the four research priorities listed above will also be considered.
Awards cannot exceed $142,000.00 USD per year for up to three years.